Synapse - Joel Sheinfeld

Search Within

Joel Sheinfeld

Results (34)

Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT)

Meeting Abstract

Jia, X.; Feldman, D. R.; Glezerman, I.; Van Alstine, L. J.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M. S.; Reich, L.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older

Journal Article

Feldman, D. R.; Voss, M. H.; Jacobsen, E. P.; Jia, X.; Suarez, J. A.; Turkula, S.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J.; Patil, S.
Cancer (2013)

Fulltext@MSK | Save

Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts)

Meeting Abstract

Feldman, D. R.; Voss, M. H.; Jia, X.; Van Alstine, L. J.; Patil, S.; Fischer, P.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J.
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design

Journal Article

Feldman, D. R.; Patil, S.; Trinos, M. J.; Carousso, M.; Ginsberg, M. S.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.
Cancer (2012)

Fulltext@MSK | Save

Clinical features of germ cell tumors (GCT) in men age 50 or older: Successful outcome and tolerability to chemotherapy for advanced disease

Meeting Abstract

Voss, M. H.; Jacobsen, E. P.; Patil, S.; Turkula, S.; Jia, X.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.; Feldman, D. R.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Patil, S.; Trinos, M. J.; Carousso, M.; Ginsberg, M. S.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: Results and prognostic factor analysis

Journal Article

Feldman, D. R.; Sheinfeld, J.; Bajorin, D. F.; Fischer, P.; Turkula, S.; Ishill, N.; Patil, S.; Bains, M.; Reich, L. M.; Bosl, G. J.; more...
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts

Meeting Abstract

Feldman, D. R.; Sheinfeld, J.; Bajorin, D. F.; Fischer, P.; Turkula, S.; Ishill, N.; Patil, S.; Bains, M.; Bosl, G. J.; Motzer, R. J.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors

Journal Article

Feldman, D. R.; Kondagunta, G. V.; Ginsberg, M. S.; Ishill, N.; Patil, S.; Cestaro, J.; Obbens, E.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J.
Investigational New Drugs (2007)

Fulltext@MSK | Save